Search
Learn how MSK's world-class Head and Neck cancer specialists help people facing throat cancer, using the latest therapies and innovations.
New MSK research uncovers unique genetic signatures in cancer patients of non-European ancestry; identifies social adversity as a potential risk factor for higher rates of triple-negative breast cancer among Black women; shows a web-based system could help head-and-neck cancer survivors report their concerns; and finds adding immunotherapy can boost the effectiveness for hard-to-treat follicular lymphomas.
MSK researchers continued to make strides against cancer in 2025. Learn about some of their top discoveries.
Cancer pain is common, even after treatment has ended, so doctors at MSK have developed a number of ways to treat cancer pain and help people get back to their lives.
El dolor por cáncer es común, incluso después de que el tratamiento haya finalizado, por lo que los médicos de MSK han desarrollado una serie de métodos para tratar el dolor por cáncer y ayudar a las personas a retomar sus vidas.
Learn how a stem cell-derived treatment shows potential for treating Parkinson's disease.
Sentinel lymph node (SLN) mapping leads to significantly less lower-extremity lymphedema compared to comprehensive lymphadenectomy (LND) after hysterectomy in patients with endometrial cancer.
The 2016 annual meeting of the American Association for Cancer Research (AACR) ended with a visit from the Vice President.
Topics included more diverse representation in clinical trials, racial disparities in colorectal cancer, and ancestry testing to improve diagnoses.
Researchers from Memorial Sloan Kettering Cancer Center (MSK) and their colleagues at the University of Pennsylvania (UPenn), in collaboration with the Parker Institute for Cancer Immunotherapy (PICI), studied changes in the blood of patients with stage IV melanoma who were all treated with the PD-1 drug pembrolizumab. Researchers looked at circulating immune cells called T cells that showed signs of being “reinvigorated” by the PD-1 therapy. For more information or to arrange interviews please e-mail Rebecca Williams at [email protected].